Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495586 | 0.94 | CHRM2 (0.49) | CHRM2CHRM3ADRB2ALDH1A1POLB | |
| SCHEMBL4476500 | 0.93 | CHRM2 (0.45) | CHRM2CHRM3ADRB2ALDH1A1POLB | |
| SCHEMBL4489644 | 0.92 | CHRM2 (0.48) | CHRM2CHRM3ADRB2 | |
| SCHEMBL267576 | 0.90 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL4483379 | 0.90 | CHRM2 (0.49) | CHRM2CHRM3ADRB2 | |
| SCHEMBL4495584 | 0.87 | CHRM2 (0.45) | CHRM2CHRM3ADRB2ALDH1A1POLB | |
| SCHEMBL4489639 | 0.85 | CHRM2 (0.45) | CHRM2CHRM3ADRB2 | |
| SCHEMBL4481938 | 0.84 | CHRM2 (0.45) | CHRM2CHRM3ADRB2ALDH1A1POLB | |
| SCHEMBL265208 | 0.84 | CHRM2 (0.61) | CHRM2CHRM3 | |
| SCHEMBL4475969 | 0.84 | CHRM2 (0.44) | CHRM2CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632847-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-15 | — | — | US | disclosed |